Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVS Supplement Deceptively Capitalizes On Proximity To AREDS-Formula Product – Complaint

This article was originally published in The Tan Sheet

Executive Summary

CVS supplement Advanced Eye Health deceives consumers by piggy-backing off NIH study findings of a Bausch + Lomb formula found to reduce eye disease progression, says a complaint seeking class action status in California state court.

You may also be interested in...



Vision Health Supplements Blurry On AREDS Formulation – Study

A study finds claims for ocular supplements cited or relied on AREDS findings even when the products did not match the formulas assessed in the research by NIH’s National Eye Institute. The products emphasize AREDS but offer little information to consumers, they say.

Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study

Promotions for Bausch & Lomb's new Ocuvite PreserVision containing vitamins C and E, beta carotene, zinc and copper likely will stress the product's clinically proven eye health benefits.

FTC Shift Under Biden Administration Begins With Chairman Simons, Senior Staff Resigning

While expected following start of Biden administration, Simon’s resignation is “somewhat of a surprise” considering it will change the balance of power to the Democrats ahead of when his term would have been ended, says advertising law attorney Ivan Wasserman.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel